Ir a las transacciones
Salud

Avacta Group has raised funds via a placing and subscription to both institutional and retail investors

Avacta Group Plc has raised US$60.3 million to continue developing next generation cancer therapies.

Avacta’s mission is to shape the future of medicine by developing safe and efficacious drugs and powerful research and diagnostic tools. Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumor-targeted chemotherapy. With this approach, the company aims to address the lack of a durable response to current immunotherapies experienced by most patients.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker, assisting Avacta’s management team and shareholders all the way from the start to the successful completion of the fundraising. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from both existing and new institutional investors, deal structuring, document preparation and the fundraise pricing and sizing.

Contáctese con el equipo de la transacción

 Geoff  Nash

Geoff Nash

Director
Londres, Reino Unido
Oaklins Cavendish

Transacciones relacionadas

PCI Pal has completed an equity raise
Servicios Financieros | TMT

PCI Pal has completed an equity raise

PCI Pal has completed a fundraising. Funds will be allocated towards several key areas, with a significant portion directed towards supporting its continued expansion in the US, focusing on marketing efforts, product marketing and enhancing engagement with key partners.

Aprenda más
Prestige Inhome Care has found a long-term strategic partner
Salud

Prestige Inhome Care has found a long-term strategic partner

Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.

Aprenda más
Cara Care has been acquired by Mahana Therapeutics
Private Equity | Salud | TMT

Cara Care has been acquired by Mahana Therapeutics

Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.

Aprenda más